HANGZHOU, China, March 7, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK, 'the Company'), a leading medical device company in the peripheral and neurovascular interventional market in China, today announced a new strategic partnership with Avinger, a commercial-stage medical device company developing and marketing the first and only intra-vascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease.

中国杭州，2024年3月7日/PRNewswire/--Zylox Tonbridge（2190.HK，“公司”）是中国外周和神经血管介入市场的领先医疗器械公司，今天宣布与Avinger建立新的战略合作伙伴关系，Avinger是一家商业级医疗器械公司，开发和销售第一个也是唯一一个血管内图像引导，基于导管的血管疾病诊断和治疗系统。

This partnership includes an exclusive right to Zylox-Tonbridge to localize, manufacture, and commercialize the entire product family developed by Avinger in Greater China (including Mainland China, Hong Kong, Taiwan, and Macau), and a technology transfer agreement to leverage Zylox-Tonbridge cost-efficient manufacturing capacity to support Avinger's global sales outside of Greater China.

该合作关系包括Zylox Tonbridge在大中华区（包括中国大陆、香港、台湾和澳门）对Avinger开发的整个产品系列进行本地化、制造和商业化的专有权，以及利用Zylox Tonbridge具有成本效益的制造能力来支持Avinger在大中华区以外的全球销售的技术转让协议。

This collaboration also provides Avinger the opportunity to distribute high-quality peripheral vascular products developed by Zylox-Tonbridge in the United States and Germany. Based on the achievement of certain milestones, Zylox-Tonbridge will invest 15.0 million USD into Avinger in two tranches by subscribing for newly issued common shares and preferred shares of Avinger..

这种合作还为Avinger提供了在美国和德国分销由Zylox Tonbridge开发的高质量外周血管产品的机会。基于某些里程碑的成就，Zylox Tonbridge将通过认购Avinger新发行的普通股和优先股，分两期向Avinger投资1500万美元。

Avinger is globally recognized for its pioneering OCT-guided, catheter-based system and devices, offering real-time intra-vascular imaging during treatment. This innovation empowers physicians to precisely identify and treat diseased vessels while minimizing vascular damage risks. Avinger's flagship products include Pantheris (an OCT-guided atherectomy device), Ocelot and Tigereye (OCT-guided CTO-crossing devices), and LightBox 3 (the OCT imaging console).

Avinger因其开创性的OCT引导、基于导管的系统和设备而获得全球认可，在治疗期间提供实时血管内成像。这项创新使医生能够精确识别和治疗患病血管，同时最大限度地减少血管损伤风险。Avinger的旗舰产品包括Pantheris（OCT引导的切除装置），Ocelot和Tigereye（OCT引导的CTO交叉装置）以及LightBox 3（OCT成像控制台）。

These products have demonstrated clinical safety and efficacy in multiple clinical trials completed by Avinger..

这些产品在Avinger完成的多项临床试验中证明了临床安全性和有效性。

According to some market research data, there are over 8 million PAD patients in the United States as of 2022. Atherectomy has become widely adopted, leading the Total Addressable Market of atherectomy devices to around 760 million USD in 2022. Compared to the U.S. market, atherectomy devices are at the initial stage to be utilized during PAD procedures in China, while it is estimated that the population of PAD patients in China was approximately 40 million as of 2020 and the number is still growing rapidly.

根据一些市场研究数据，截至2022年，美国有800多万PAD患者。无神论切除术已被广泛采用，导致2022年无神论切除装置的总可寻址市场达到约7.6亿美元。与美国市场相比，中国PAD手术中使用的切除装置尚处于初始阶段，而据估计，截至2020年，中国PAD患者人数约为4000万，并且数量仍在迅速增长。

Driven by the increasing penetration of drug-coated balloons in interventional procedures, the demand for better vessel preparation and atherectomy devices to optimize post-intervention results is growing..

由于药物涂层球囊在介入手术中的渗透性越来越高，对更好的血管准备和动脉切除装置的需求正在增加，以优化干预后的结果。

By collaborating with Avinger, Zylox-Tonbridge is introducing the globally leading OCT-guided vascular treatment technology to the Chinese peripheral intervention market. The collaboration is anticipated to further bolster Zylox-Tonbridge's peripheral product portfolio for PAD, making another step toward achieving its strategic goal of offering a comprehensive solution in peripheral vascular Intervention medical devices.

通过与Avinger的合作，Zylox Tonbridge将全球领先的OCT引导血管治疗技术引入中国外周干预市场。预计此次合作将进一步巩固Zylox Tonbridge针对PAD的外围产品组合，朝着实现其在外围血管介入医疗设备中提供全面解决方案的战略目标迈出又一步。

Furthermore, Zylox-Tonbridge will leverage its robust and cost-effective manufacturing capabilities to enhance Avinger's global market competitiveness. The partnership represents a progressive stride in Zylox-Tonbridge's mission to expand globally and bring high-quality and affordable medical products and services to patients worldwide..

此外，Zylox Tonbridge将利用其强大且具有成本效益的制造能力来增强Avinger的全球市场竞争力。该合作关系代表着Zylox Tonbridge在全球扩张并为全球患者带来高质量和负担得起的医疗产品和服务的使命上迈出了一大步。

Dr. Jonathon ZHAO, Chairman and CEO of Zylox-Tonbridge, said, 'We are pleased to partner with Avinger to provide Chinese healthcare professionals and patients with cutting-edge medical technologies and innovative products. We believe this collaboration will expand the company's Peripheral Vascular Intervention product portfolio, reinforcing our market leadership, and accelerating the growth of the vessel preparation business in China's peripheral vascular intervention market.

Zylox Tonbridge董事长兼首席执行官Jonathon ZHAO博士说，“我们很高兴与Avinger合作，为中国医疗保健专业人士和患者提供尖端医疗技术和创新产品。我们相信，此次合作将扩大公司的外周血管介入产品组合，巩固我们的市场领导地位，并加速中国外周血管介入市场血管制剂业务的增长。

Leveraging our advanced manufacturing capabilities and working with Avinger, we are confident in bringing more cost-efficient and high-quality products to patients. We are looking forward to cooperating with global partners to capitalize on growing market opportunities by offering high-quality and affordable innovative medical products and services for all.'.

利用我们的先进制造能力并与Avinger合作，我们有信心为患者带来更具成本效益和高质量的产品。我们期待着与全球合作伙伴合作，通过为所有人提供高质量和负担得起的创新医疗产品和服务，利用不断增长的市场机会。”

'We are excited to announce this strategic transaction with Zylox-Tonbridge, a dynamic leader in the peripheral interventional market in China,' said Jeffrey M. Soinski, Avinger's President and CEO. 'Our broad-reaching partnership creates an exciting new pathway for Avinger products to enter the large and growing Greater China market through an established commercial channel.

Avinger总裁兼首席执行官杰弗里·索因斯基（JeffreyM.Soinski）说，我们很高兴宣布与ZyloxTonbridge达成这项战略交易，ZyloxTonbridge是中国外围介入市场的活跃领导者我们广泛的合作伙伴关系为Avinger产品通过既定的商业渠道进入庞大且不断增长的大中华市场开辟了一条令人兴奋的新途径。

It also provides the opportunity for a more cost-efficient manufacturing structure to support the growth of global sales, as well as the potential for Avinger to access Zylox-Tonbridge's high-quality peripheral products for distribution in the U.S. and Germany.'.

它还提供了一个更具成本效益的制造结构的机会，以支持全球销售的增长，以及Avinger获得Zylox Tonbridge高质量外围产品在美国和德国分销的潜力。”

About Zylox-Tonbridge:

关于归创通桥：

Zylox-Tonbridge is one of the leading players in the neuro- and peripheral-vascular interventional medical device market in China. The Company was founded in 2012 and is headquartered in Hangzhou, China.

Zylox Tonbridge是中国神经和外周血管介入医疗器械市场的领先者之一。该公司成立于2012年，总部位于中国杭州。

As an integrated medical device company supported by our in-house R&D and manufacturing capabilities, proprietary technological platforms, and commercialization capabilities, we strive to provide patients with high-quality and affordable medical devices and services, so that everyone has access to the high-quality life brought by advanced medical technology..

作为一家由我们内部研发和制造能力、专有技术平台和商业化能力支持的综合医疗器械公司，我们努力为患者提供高质量和负担得起的医疗器械和服务，使每个人都能享受先进医疗技术带来的高质量生活。

About Avinger, Inc.

关于Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first image-guided, catheter-based system for the diagnosis and treatment of patients with vascular disease in the peripheral and coronary arteries. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox series of imaging consoles, the Ocelot and Tigereye® family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices for the treatment of peripheral artery disease (PAD), estimated to affect more than 200 million people worldwide.

Avinger是一家商业化的医疗器械公司，设计并开发了第一个基于图像引导的导管系统，用于诊断和治疗外周动脉和冠状动脉血管疾病患者。Avinger致力于通过其Lumivascular平台从根本上改变血管疾病的治疗方式，该平台目前由Lightbox系列成像控制台，Ocelot和Tigereye®慢性完全闭塞（CTO）导管家族以及Pantheris®用于治疗外周动脉疾病（PAD）的切除装置家族组成，估计影响全球2亿多人。

Avinger is developing its first product application for the treatment of coronary artery disease (CAD), an image-guided system for CTO-crossing in the coronary arteries, which provides the opportunity to redefine a large and underserved market. Avinger is based in Redwood City, California.

Avinger正在开发其第一个用于治疗冠状动脉疾病（CAD）的产品应用程序，这是一种用于冠状动脉CTO交叉的图像引导系统，它为重新定义一个庞大且服务不足的市场提供了机会。Avinger总部位于加利福尼亚州红木市。